S
Susan L. Greenspan
Researcher at University of Pittsburgh
Publications - 275
Citations - 20761
Susan L. Greenspan is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Osteoporosis & Bone density. The author has an hindex of 76, co-authored 265 publications receiving 19032 citations. Previous affiliations of Susan L. Greenspan include Beth Israel Deaconess Medical Center & Harvard University.
Papers
More filters
Journal ArticleDOI
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.
Susan L. Greenspan,Ronald D. Emkey,Henry G. Bone,Stuart R. Weiss,Norman H. Bell,Robert W. Downs,Clark McKeever,Sam S. Miller,Michael H. Davidson,Michael A. Bolognese,Anthony L. Mulloy,Norman Heyden,Mei X. Wu,Amarjot Kaur,Antonio Lombardi +14 more
TL;DR: In this paper, a double-blind, placebo-controlled discontinuation trial was conducted to determine the rate of bone loss when therapy with alendronate, estrogen, or both agents is discontinued.
Journal ArticleDOI
Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists.
S. Aubrey Stoch,Robert A. Parker,Liping Chen,Glenn J. Bubley,Yoo-Joung Ko,Aimee Vincelette,Susan L. Greenspan +6 more
TL;DR: In this paper, the authors compared bone mineral density (BMD), biochemical markers of bone turnover, and body composition in 60 men with prostate cancer (19 men receiving androgen deprivation therapy and 41 eugonadal men) and BMD in 197 community living healthy controls of similar age.
Journal ArticleDOI
Precision and Discriminatory Ability of Calcaneal Bone Assessment Technologies
Susan L. Greenspan,Mary L. Bouxsein,Mary E. Melton,Andrea H Kolodny,James H. Clair,Paul DeLucca,Michael Stek,Kenneth G. Faulkner,Eric S. Orwoll +8 more
TL;DR: Although the precision is variable, the calcaneal QUS and SEXA instruments can discriminate between osteoporotic patients and young normal controls and appear to be a useful technique for assessment of osteoporeosis.
Journal Article
Significant Differential Effects of Alendronate, Estrogen, or Combination Therapy on the Rate of Bone Loss after Discontinuation of Treatment of Postmenopausal Osteoporosis
Susan L. Greenspan,Ronald D. Emkey,Henry G. Bone,Stuart R. Weiss,Norman H. Bell,Robert W. Downs,Clark McKeever,Sam S. Miller,Michael H. Davidson,Michael A. Bolognese,Anthony L. Mulloy,Norman Heyden,Mei X. Wu,Amarjot Kaur,Antonio Lombardi +14 more
TL;DR: Examination of the rate of bone loss after discontinuation of 2 years of alendronate therapy, hormone replacement therapy, or combination therapy found combination therapy was safe and resulted in normal findings on histologic examination of bone.
Journal ArticleDOI
Femoral Bone Strength and Its Relation to Cortical and Trabecular Changes After Treatment With PTH, Alendronate, and Their Combination as Assessed by Finite Element Analysis of Quantitative CT Scans
Tony M. Keaveny,Paul F. Hoffmann,Mandeep Singh,Lisa Palermo,John P. Bilezikian,Susan L. Greenspan,Dennis M. Black +6 more
TL;DR: Femoral strength changes with these various treatments were dominated by trabecular changes, and although changes in the cortical bone and overall bone geometry did contribute to femoralstrength changes, the extent of these latter effects depended on the type of treatment.